S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RLMD · Relmada Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Relmada Therapeutics Inc (RLMD)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.19
-0.18
(-5.34%)
● At close: October 21 at 4:00:00 PM EDT
$3.26
+0.05
(+1.56%)
Overnight:
8:05:58 PM EDT
DAY'S RANGE
$3.19
$3.19
$3.38
52-WEEK RANGE
$3.19
$1.97
$8.00
What's happening
- RLMD is down 5.34% today, trading at $3.19. — Live quote
- Volume today (142,167) is well below its 3-month average of 1,607,380. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.11 actual vs. $-0.20 estimated (+45.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RLMD
-30.43%
vs S&P 500
-43.21%
1-YEAR RETURN
RLMD
+48.67%
vs S&P 500
+34.11%
6-MONTH RETURN
RLMD
-52.00%
3-MONTH RETURN
RLMD
-36.60%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.11
Est. $-0.20
BEAT +45.9%
2026-04-26 (Q1 2026)
$-0.22
Est. $-0.20
MISS -10.6%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.14
MISS -103.1%
2025-10-26 (Q3 2025)
$-0.30
Est. $-0.12
MISS -153.6%
Valuation Measures & Ratios
Enterprise Value4$332.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)34401.03
Price / Book73.51
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-47.52%
Return on Assets (ROA9)-43.97%
Avg Volume (3M)1,607,380
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $812.4M | $601.0M | $67.8M | $20.6M | $8.2M |
| P/E | -15.65 | -10.62 | -1.14 | -0.31 | -0.10 |
| Price/Book | 3.93 | 2.75 | 7.16 | 1.29 | 0.36 |
| ROE | -25.14% | -25.86% | -625.88% | -419.57% | -351.51% |
| ROA | -23.70% | -24.03% | -398.24% | -316.91% | -284.98% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short13,424,126
Change from Prior Settlement-7.19%
% of Float—
Days to Cover (Short Ratio)12.99
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +48.7%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-11; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RLMD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$19.5M | -$10.3M | -$10.2M | -$18.2M | -$23.0M | -$18.8M | -$23.0M |
| Net income | -$12.9M | -$19.1M | -$10.1M | -$9.9M | -$17.6M | -$21.7M | -$17.8M | -$21.8M |
| EPS (diluted) | $-0.11 | $-0.22 | $-0.30 | $-0.30 | $-0.58 | $-0.72 | $-0.59 | $-0.72 |
| EPS (basic) | $-0.11 | $-0.22 | $-0.30 | $-0.30 | $-0.58 | $-0.72 | $-0.59 | $-0.72 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $219.1M | $235.4M | $94.0M | $14.9M | $21.1M | $27.7M | $45.8M | $55.7M |
| Total liabilities | $12.5M | $16.6M | $7.5M | $5.4M | $5.2M | $5.2M | $10.3M | $8.1M |
| Stockholders' equity | $206.6M | $218.7M | $86.5M | $9.5M | $15.9M | $22.4M | $35.5M | $47.6M |
| Total current assets | $219.0M | $235.3M | $94.0M | $14.9M | $21.1M | $27.7M | $45.8M | $55.7M |
| Total current liabilities | $7.4M | $12.9M | $6.4M | $5.2M | $5.1M | $5.2M | $10.3M | $8.1M |
| Cash & equivalents | $11.3M | $9.8M | $3.5M | $1.4M | $1.4M | $1.1M | $3.9M | $1.5M |
| Marketable securities (current) | $206.4M | $224.2M | $89.5M | $12.5M | $19.3M | $25.9M | $41.1M | $52.6M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Other non-current assets | $19.5K | $19.5K | $19.5K | $22.0K | $22.0K | $22.0K | $22.0K | $22.0K |
| Accounts payable | $2.4M | $5.7M | $1.6M | $1.5M | $1.4M | $1.3M | $4.1M | $2.3M |
| Accrued liabilities | $5.0M | $7.2M | $4.9M | $3.7M | $3.8M | $4.0M | $6.2M | $5.7M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $106.7K | $104.9K | $73.3K | $33.2K | $33.2K | $33.2K | $30.2K | $30.2K |
| Retained earnings | -$730.2M | -$717.3M | -$698.3M | -$678.4M | -$668.3M | -$658.4M | -$640.9M | -$622.2M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.6M | -$15.1M | -$14.6M | -$6.7M | -$6.4M | -$18.1M | -$8.8M | -$16.7M |
| Investing cash flow | $17.6M | -$135.2M | -$76.9M | $6.8M | $6.7M | $15.4M | $11.3M | $16.1M |
| Financing cash flow | -$6.4M | $156.6M | $93.6M | $0 | -$73.0K | — | -$172.5K | -$89.6K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $902.9K | $956.2K | $2.4M | $4.5M | $3.4M | $3.6M | $6.7M | $7.9M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$922.2K | $1.8M | $115.8K | $91.2K | $96.9K | -$2.9M | $1.8M | -$1.8M |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | $6.5M | $3.4M | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M |
| EPS (diluted) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 |
| EPS (basic) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M |
| Stockholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M |
| Total current assets | $94.0M | $45.8M | $97.5M | $152.9M | $223.3M |
| Total current liabilities | $6.4M | $10.3M | $12.2M | $12.5M | $15.1M |
| Cash & equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M |
| Marketable securities (current) | $89.5M | $41.1M | $92.2M | $142.9M | $167.5M |
| Accounts receivable | — | — | — | $512.4K | — |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — |
| Other non-current assets | $19.5K | $22.0K | $43.1K | $34.9K | $28.3K |
| Accounts payable | $1.6M | $4.1M | $3.5M | $5.3M | $11.2M |
| Accrued liabilities | $4.9M | $6.2M | $8.7M | $7.2M | $3.9M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $73.3K | $30.2K | $30.1K | $30.1K | $27.7K |
| Retained earnings | -$698.3M | -$640.9M | -$560.9M | -$462.1M | -$305.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M |
| Investing cash flow | -$48.1M | $51.6M | $50.5M | $19.7M | -$54.1M |
| Financing cash flow | $93.6M | -$40.3K | -$98.5K | $45.0M | $187.9M |
| Capital expenditures | — | — | — | — | — |
| Share-based compensation | $13.9M | $30.2M | $43.8M | $44.2M | $40.5M |
| Change in accounts receivable | — | — | — | $512.4K | — |
| Change in inventory | — | — | — | — | — |
| Change in accounts payable | -$2.6M | $624.6K | -$1.8M | $421.0K | $2.8M |
| Purchases of investments | — | — | — | $47.3M | $223.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RLMD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-16 to 2026-09-10
Recent transactions
- Insiders have net bought 400,000 shares over the last 182 days, across 4 purchases and 0 sales.
- Most recent: Shenouda Maged (Chief Financial Officer) — Open market purchase of 79,800 shares on 2026-09-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)400,000 sh(4 txns)
Sales (open market)0 sh(0 txns)
Net Shares+400,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer | Open market purchase | 2026-09-10 | 79,800 |
| TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 2026-09-10 | 100,000 |
| Ence Chuck | CAO and COO | Open market purchase | 2025-11-05 | 136,000 |
| Kelly Paul Edward | Chief Operating Officer | Open market purchase | 2025-11-05 | 90,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-10 | Shenouda Maged | Chief Financial Officer | Open market purchase | 79,800 | $4.25 |
| 2026-09-10 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 100,000 | $4.10 |
| 2026-09-09 | Shenouda Maged | Chief Financial Officer | Open market purchase | 120,200 | $4.20 |
| 2026-09-09 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 100,000 | $4.18 |
| 2025-12-15 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 27,500 | $4.12 |
| 2025-12-15 | Shenouda Maged | Chief Financial Officer | Open market purchase | 11,665 | $4.12 |
| 2025-11-05 | Shenouda Maged | Chief Financial Officer | Open market purchase | 500,000 | $2.20 |
| 2025-11-05 | Ence Chuck | CAO and COO | Open market purchase | 136,000 | $2.20 |
| 2025-11-05 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 272,500 | $2.20 |
| 2025-11-05 | Kelly Paul Edward | Chief Operating Officer | Open market purchase | 90,000 | $2.20 |
| 2025-08-28 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 55,976 | $0.74 |
| 2025-08-27 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 129,455 | $0.67 |
| 2025-08-26 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 80,545 | $0.62 |
| 2025-05-20 | Shenouda Maged | Chief Financial Officer | Open market purchase | 60,000 | $0.52 |
| 2025-05-20 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 147,686 | $0.56 |
| 2025-05-19 | Shenouda Maged | Chief Financial Officer | Open market purchase | 90,000 | $0.49 |
| 2025-05-19 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 30,000 | $0.50 |
| 2025-05-16 | Kelly Paul Edward | Chief Operating Officer | Open market purchase | 200,000 | $0.43 |
| 2025-05-16 | Shenouda Maged | Chief Financial Officer | Open market purchase | 50,000 | $0.44 |
| 2025-05-16 | Ence Chuck | CA and CO | Open market purchase | 228,961 | $0.45 |
| 2025-05-16 | TRAVERSA SERGIO | Chief Executive Officer | Open market purchase | 172,314 | $0.45 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:00 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-03 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-28 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-05-28 | 8-K | 2026-05-27 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-20 | 8-K | 2026-03-19 | View on SEC.gov → |
| 2026-03-19 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-09 | 8-K | 2026-03-09 | View on SEC.gov → |
Recent news
Headlines about RLMD (Relmada Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
SUNS,BNL,BCDA,FG,NTHI,ZOMDF,BATRA,ATLO,OPAL,MRP,NEOG,PEB,LTRX,SAIC,NEWT,MTDR,VG,LUCK,EVH,RLMD,BUSE,IRIX,RNXT,BLNE | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-21 -
SUNS,FG,BNL,BCDA,ZOMDF,NTHI,BATRA,ATLO,OPAL,MRP,NEOG,PEB,LTRX,SAIC,NEWT,VG,MTDR,LUCK,EVH,RLMD,IRIX,BUSE,RNXT,BLNE | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
BNL,NTHI,IMRX,ATLO,OPAL,SDHC,VSH,PEB,INNV,NEWT,GRNT,ABR,MTDR,LUCK,GROV,RLMD,DOC,IRIX,BUSE,BLNE | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
BNL,NTHI,ATLO,IMRX,OPAL,SDHC,VSH,PEB,INNV,GRNT,NEWT,MTDR,ABR,LUCK,GROV,RLMD,IRIX,BUSE,HURC,BLNE | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-20 -
EG,STAA,LCNB,SLND,VANI,CODI,GRNT,ABR,TPL,CAUD,RLMD,GUG,QRHC,COLB | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-20 -
Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call
Benzinga · 2026-10-12 -
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
Benzinga · 2026-10-08 -
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement
Seeking Alpha · 2026-09-14
No headlines in this category right now — try “All”.